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OBJECTIVES The aims of this analysis were to describe the clinical characteristics, management, and
outcomes of patients hospitalized for acute decompensated heart failure (HF) with preserved
systolic function (PSF).
BACKGROUND Clinically meaningful characteristics of these patients have not been fully studied in a large
database.
METHODS Data from100,000 hospitalizations from the Acute Decompensated Heart Failure National
Registry (ADHERE) database were analyzed.
RESULTS Heart failure with PSF was present in 50.4% of patients with in-hospital assessment of left
ventricular function. When compared with patients with systolic dysfunction, patients with
PSF were more likely to be older, women, and hypertensive and less likely to have had a prior
myocardial infarction or be receiving an angiotensin-converting enzyme inhibitor or angio-
tensin II receptor blocker. In-hospital mortality was lower in patients with PSF compared
with patients with systolic dysfunction (2.8% vs. 3.9%; adjusted odds ratio [OR]: 0.86; p 
0.005), but duration of intensive care unit stay and total hospital length of stay were similar.
Serum creatinine 2 mg/dl was associated with increased in-hospital mortality in both
systolic function groups (PSF: 4.8%; systolic dysfunction: 8.4%; p  0.0001), and the most
powerful predictors of in-hospital mortality in both groups were blood urea nitrogen 37
mg/dl (OR: 2.53; 95% confidence interval [CI]: 2.22 to 2.87) and systolic blood pressure
125 mm Hg (OR: 2.58; 95% CI: 2.33 to 2.86).
CONCLUSIONS Heart failure with PSF is common and is characterized by a unique patient profile. Event rates
are worrisome and reflect a need for more effective management strategies. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.022Cardiol 2006;47:76–84) © 2006 by the American College of Cardiology Foundation
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datients living with heart failure (HF) experience approxi-
ately 1 million annual hospitalizations for HF (1). About
ne-half of these hospitalizations may occur in patients who
ave HF with preserved systolic function (PSF), typically
efined as symptomatic HF occurring in the setting of a
easured left ventricular (LV) ejection fraction40% (2,3).
Heart failure with PSF has not been studied as exten-
ively as HF with systolic dysfunction. The limited data that
re available in patients hospitalized for HF with PSF
From the *Division of Cardiology, Department of Medicine, University of Texas
outhwest Medical Center, Dallas, Texas; †Department of Biostatistics, Scios Inc.,
remont, California; ‡Cardiovascular Division, Brigham and Women’s Hospital,
oston, Massachusetts; §Division of Cardiology, Department of Medicine, Univer-
ity of California, San Francisco, San Francisco, California; and Ahmanson-UCLA
ardiomyopathy Center, UCLA Medical Center, Los Angeles, California. The
DHERE database and this study were funded by Scios Inc. Drs. Yancy, Warner
tevenson, De Marco, and Fonarow are research, consultants, and speakers for Scios
nc. Ms. Lopatin is an employee of Department of Biostatistics of Scios Inc.i
Manuscript received March 25, 2005; revised manuscript received August 17, 2005,
ccepted September 8, 2005.uggest that demographic characteristics, comorbidities, HF
tiology, and pathology differ from those of patients with
ystolic dysfunction (2–6). Patients with PSF are usually
lder, more often women, and more likely to be obese than
hose with systolic dysfunction (2–6). In addition, patients
ith PSF typically have a left ventricle that is normal in size
ut has abnormal relaxation properties; in contrast, patients
ith systolic dysfunction usually have a left ventricle that is
ilated but relaxes normally (5,6). Despite these differences,
owever, the clinical features of HF with PSF are similar to
hose of HF with systolic dysfunction and typically include
vidence of volume overload, reduced exercise capacity, and
mpaired quality of life (3,4).
Important data are lacking regarding management, clin-
cal outcomes, and predictors of in-hospital mortality for
atients with HF and PSF. As a separate issue, renal
ysfunction is an emerging risk factor for increased mortal-
ty and worsening HF in patients with systolic dysfunction,
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January 3, 2006:76–84 HF With Preserved Systolic Function in the ADHERE Databaseut similar data for patients with PSF are not available
7–11). Expanding the database relating to HF with PSF is
ssential for designing truly relevant clinical investigations
n the future.
The primary goals of the present analysis were to char-
cterize the clinical features, management, and outcomes of
atients hospitalized for HF with PSF and to identify
linically relevant differences in these parameters from the
ame measures in patients hospitalized for HF with systolic
ysfunction. A large cohort of patients from the Acute De-
ompensated Heart Failure National Registry (ADHERE)
atabase served as the source of clinical data.
ETHODS
he ADHERE procedures and the patients’ characteristics
hat the registry tracks have been previously described (12).
riefly, medical records are retrospectively reviewed at
articipating sites by the research coordinator, and data
rom consecutive eligible male and female patients 18
ears of age at the time of hospital admission are entered
nto the registry electronically (12). These data include
emographic information, medical history, baseline clinical
haracteristics, initial evaluation, treatment received, proce-
ures performed, hospital course, and patient disposition.
mportantly, registry participation does not require any
lteration of treatment or hospital care, and entry of data
nto the registry is not contingent on the use of any
articular therapeutic agent or treatment regimen. Institu-
ional review board approval is required for all participating
enters; however, informed consent of individuals is not
equired for registry entry (12). In order to preserve patient
onfidentiality, direct patient identifiers are not collected.
egistry entries thus reflect individual hospitalization events
r “patient episodes,” not individual patients, and multiple
ospitalizations of the same patient may be entered into the
egistry as separate records. Longitudinal outcomes for each
atient are not available.
tatistical analyses. Data from the ADHERE database
ere used for retrospective analyses of clinical characteris-
ics, treatments, and outcomes for patient episodes of HF
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ADHERE  Acute Decompensated Heart Failure
National Registry
ARB  angiotensin II receptor blocker
BP  blood pressure
BUN  blood urea nitrogen
CART  classification and regression tree
CI  confidence interval
HF  heart failure
LV  left ventricular
OR  odds ratio
PSF  preserved systolic functionith PSF (LV ejection fraction 40%) or systolic dysfunc- tion (LV ejection fraction 40%), based on the availability
f LV ejection fraction assessment during hospitalization.
nivariate comparisons between different groups were per-
ormed using chi-square, analysis of variance, and Wilcoxon
ests, as appropriate. Two-sided p values were reported. In
ddition, mortality in the two systolic function groups was
ompared using logistic regression adjusted for mortality
isk factors (described in later text). The effect of renal
nsufficiency (defined as serum creatinine 2 mg/dl) on
ortality was evaluated separately in the two systolic func-
ion groups using logistic regression. To address the con-
ounding circumstance of multiple readmissions of the same
atients, the mortality analysis was also performed in a
ubset of unique patients with a first admission for HF. The
osmer-Lemeshow test and the area under the receiver-
perator curve were used to assess the fit and the discrim-
nation of the models, respectively. Unless otherwise noted,
hese analyses were performed using version 8.2 of SAS
oftware (SAS Institute Inc., Cary, North Carolina).
ortality risk factors. Owing to anticipated differences in
edical history and clinical characteristics at presentation
etween the two systolic function groups, it was important
o adjust the mortality comparison for relevant prognostic
actors. Because the number of collected characteristics was
arge and because certain data for some patient episodes
ere missing, a classification and regression tree (CART)
nalysis was used as a primary tool to identify key mortality
redictors for all patient episodes with in-hospital LV
jection fraction assessments (13). The CART analysis is a
onparametric statistical method based on recursive parti-
ioning that creates a binary decision tree, with a split in
ach node identifying the optimal discrimination value for a
pecified outcome variable. Patient episodes with missing
ata for a given predictor variable were included in the
nalysis using surrogate variables with information similar
o that contained in the primary splitter variable. The tree
as constrained to have at least 1,000 patient episodes in the
arent nodes and at least 500 patient episodes in the final
odes, and its predictive ability was assessed using 10-fold
ross-validation. The analysis was implemented using ver-
ion 5.0 of CART software developed by Salford Systems
San Diego, California).
Of almost 80 demographic, medical history, and initial
valuation variables collected in the ADHERE database, 51
ariables satisfied predetermined criteria of no more than
% missing and at least 2% event frequency (for dichoto-
ous variables). The following variables were analyzed: 3
emographic (age, gender, race [African American vs.
ther]); 20 medical history (history of atrial fibrillation,
ctive malignancy, coronary artery disease, coronary artery
isease diagnosis by angiogram, cardiac valvular disease,
hronic obstructive pulmonary disease/asthma, chronic re-
al insufficiency, chronic renal dialysis, diabetes, HF, hy-
erlipidemia/dyslipidemia, hypertension, implantable
ardioverter-defibrillator, liver disease, myocardial infarc-
ion, pacemaker, peripheral vascular disease, revasculariza-
t
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HF With Preserved Systolic Function in the ADHERE Database January 3, 2006:76–84ion, stroke, ventricular tachycardia/fibrillation); 15 chronic
edications (diuretics, angiotensin-converting enzyme
ACE] inhibitors, angiotensin II receptor blockers [ARBs],
nti-arrhythmics, aspirin, beta-blockers, calcium channel
lockers, clopidogrel, digoxin, glitazone, lipid-lowering
gents, nitrate, nonsteroidal anti-inflammatory drugs, pe-
ipheral vasodilators, warfarin); 12 initial evaluation assess-
ents (atrial fibrillation on electrocardiogram, blood urea
itrogen [BUN], creatinine, diastolic blood pressure [BP],
ystolic BP, heart rate, hemoglobin, sodium, dyspnea at rest,
atigue, peripheral edema, rales); and insurance type (Medi-
are/Medicaid vs. other). For most (41 of 51) variables,
ewer than 0.09% of the values were missing, but for six
ariables, more than 1% of the values were missing in
atient episodes with in-hospital LV ejection fraction as-
essments.
Findings from the CART analyses were supported by
ultiple logistic regression analysis based on complete cases.
ESULTS
s of January 2004, the ADHERE database included
05,388 patient admissions for HF at 274 centers. Left
entricular ejection fraction was quantitatively determined
uring hospitalization in 52,187 (49.52%) of these admis-
ions. In this population, 26,322 admissions (50.4%) pre-
ented with PSF.
In the remaining patient hospitalizations (n  53,201),
ualitative assessment of in-hospital LV ejection fraction
normal, mild, moderate, or severe impairment) was avail-
ble in 7,594 cases (14.3%), with no information about
n-hospital LV ejection fraction in the remaining 45,607
atient admissions. The measurement of LV ejection frac-
ion in the group with qualitative LV ejection fraction
ssessment demonstrated the presence of intact systolic
able 1. Demographic Characteristics and Medical History
Characteristic
Systolic
Preserved
(n  26,322)
ge (yrs, mean  SD) 73.9  13.2
omen (%) 62
dmission at academic center (%) 30
edicare/Medicaid insurance (%) 80
frican American (%) 17
ypertension, CAD, or diabetes (%) 91
ypertension (%) 77
AD (%) 50
iabetes mellitus (%) 45
hronic renal insufficiency (%) 26
istory of heart failure (%) 63
rior myocardial infarction (%) 24
OPD or asthma (%) 31
ardiac valvular disease (%) 21
eripheral vascular disease (%) 17
entricular tachycardia (%) 3
Comparison between preserved and reduced systolic function groups.
CAD  coronary artery disease; COPD  chronic obstructive pulmonary diseasunction in 71% of patient episodes. Descriptive data on this broup are very similar to the PSF group. The data regarding
he group without an in-hospital assessment of LV ejection
raction are clinically distinct and reflect an apparent higher
isk profile. These data are shown in the tables, but are not
he focus of this manuscript.
emographics and clinical characteristics. Demograph-
cs and characteristics of the past medical history for patient
pisodes of HF with PSF are shown in Table 1. These
pisodes were characterized by advanced age, predominance
f female gender, and a lower proportion of African Amer-
cans. More than 90% of patient episodes with PSF had a
istory of hypertension, coronary artery disease, or diabetes.
dditionally, a prior history of HF was present in almost
wo-thirds of patient episodes with PSF, and a history of a
rior myocardial infarction was present in 24%.
linical presentation. Clinical characteristics of patient ep-
sodes of HF with PSF at presentation are shown in Table 2.
pisodes of HF with PSF were associated with a generally
igher systolic BP, resulting in a higher rate of systolic
ypertension (systolic BP140 mm Hg) and a lower rate of
ypotension (systolic BP 90 mm Hg). In addition, heart
ate was lower and atrial fibrillation and peripheral edema
ccurred more often. The frequency of dyspnea at rest and
arameters of renal function were similar for both groups.
anagement. Before hospitalization, approximately two-
hirds of patient episodes of HF with PSF were treated with
iuretics (Table 3). The use of an ACE inhibitor or an
RB, use of digoxin, and use of spironolactone occurred less
ften in patient episodes with PSF compared with those
ith systolic dysfunction. Conversely, beta-blocker use was
lightly higher in patient episodes with PSF compared with
hose with systolic dysfunction.
During hospitalization, the use of oral therapies for HF
ncreased relative to the before-hospitalization period in
ction
p*
No LVEF
Assessment
(n  45,607)
Reduced
(n  25,865)
69.8  14.4 0.0001 72.8  14.1
40 0.0001 51
35 0.0001 33
73 0.0001 81
22 0.0001 22
88 0.0001 92
69 0.0001 72
59 0.0001 61
40 0.0001 46
26 0.98 35
72 0.0001 86
36 0.0001 33
27 0.0001 33
22 0.13 24
17 0.33 19
11 0.0001 10
F  left ventricular ejection fraction.Funoth groups, but more so for patient episodes with systolic
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January 3, 2006:76–84 HF With Preserved Systolic Function in the ADHERE Databaseysfunction (Tables 3 and 4). With the exception of ARBs,
ll oral medications were used significantly less often during
atient episodes with PSF (Table 4). Furthermore, the
ifference in the use of these agents became greater during
ospitalization (Tables 3 and 4). For example, the use of an
CE inhibitor in patients without diabetes increased by
3% in patient episodes with PSF, compared with 82% in
atient episodes with systolic dysfunction.
Whereas the use of intravenous diuretics during hospi-
alization was high in patient episodes with PSF, parenteral
asodilators, nesiritide, and inotropes were used infre-
uently and significantly less often than in patient episodes
ith systolic dysfunction (Table 4).
The pattern of use of oral therapy for HF at discharge
Table 5) was similar to that reported before (Table 3) and
uring hospitalization (Table 4). Diuretic use remained
igh in both groups, whereas the use of ACE inhibitors or
RBs, use of beta-blockers, use of digoxin, and use of
pironolactone was lower for patient episodes of HF with
SF.
able 2. Clinical Presentation
Characteristic
Systo
Preserved
(n  26,322)
dmission to ED or observation unit (%) 79
dmission to intensive care unit (%) 14
eripheral edema (%) 69
ales (%) 69
ystolic BP 140 mm Hg (%) 61
ystolic BP (mm Hg, mean  SD) 152.5  32.7
ystolic BP 90 mm Hg (%) 1
iastolic BP (mm Hg, mean  SD) 78.7  20.6
nitial serum Cr (mg/dl, mean  SD) 1.7  1.5
erum Cr 2 mg/dl (%) 17
UN (mg/dl, mean  SD) 29.3  19.3
eart rate (beats/min, mean  SD) 86.8  22.0
yspnea at rest (%) 34
trial fibrillation on first ECG (%) 21
Comparison between preserved and reduced systolic function groups.
BP  blood pressure; BUN  blood urea nitrogen; Cr  creatinine; ECG  ele
able 3. Use of Non-Intravenous Medications Before Hospitaliza
Medication
S
Preserved
(n  26,322
iuretic (%) 64.8
CE inhibitor (%) 36.1
Patients without history of diabetes, n/total (%) 4,468/14,501 (3
Patients with history of diabetes, n/total (%) 5,026/11,800 (4
RB (%) 12.7
CE inhibitor or ARB (%) 47.3
eta-blocker (%) 45.5
Patients without history of MI, n/total (%) 8,262/19,956 (4
Patients with history of MI, n/total (%) 3,717/6,345 (58
igoxin (%) 18.7
pironolactone (%) 5.4Comparison between preserved and reduced systolic function groups.
ACE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocker; LVEutcomes during hospitalization. Clinical outcomes dur-
ng hospitalization are shown in Table 6. In-hospital mor-
ality was significantly lower for patient episodes of HF with
SF compared with episodes with systolic dysfunction.
ength of stay in the two groups was similar, but the need
or intensive care unit management was significantly lower
n patient episodes of HF with PSF. The proportion of
atients losing weight during hospitalization and the propor-
ion discharged with persistent symptomatic HF of mild-to-
oderate severity was similar in both groups.
djusted mortality analysis. On the basis of data from all
atient episodes with quantitative in-hospital LV ejec-
ion fraction assessments, CART analysis identified ele-
ated BUN, lower systolic BP, low sodium, older age,
levated creatinine, presence of dyspnea at rest, and
bsence of chronic beta-blocker use as mortality risk
actors. Among these variables, the two main contribu-
ors to higher mortality (the top splits in the tree) were
UN 37 mg/dl and systolic BP 125 mm Hg. When
he CART analysis was carried out in the PSF and
unction
p*
No LVEF
Assessment
(n  45,607)
Reduced
(n  25,865)
75 0.0001 79
18 0.0001 12
63 0.0001 65
67 0.0002 67
44 0.0001 46
138.9  30.9 0.0001 140.9  32.5
4 0.0001 4
80.0  20.4 0.0001 76.0  19.7
1.6  1.3 0.0281 1.9  1.8
18 0.57 24
30.2  19.8 0.0001 34.5  22.5
92.9  22.7 0.0001 86.7  20.7
34 0.19 35
17 0.0001 20
rdiogram; ED  emergency department; LVEF  left ventricular ejection fraction.
c Function
p*
No LVEF Assessment
(n  45,607)
Reduced
(n  25,865)
65.5 0.14 76.6
42.5 0.0001 43.4
5,898/15,376 (38.4) 0.0001 10,290/24,814 (41.5)
5,076/10,465 (48.5) 0.0001 9,489/20,753 (45.7)
10.9 0.0001 12.2
52.3 0.0001 54.3
44.2 0.0026 52.4
6,377/16,587 (38.4) 0.0001 14,727/30,517 (48.3)
5,053/9,254 (54.6) 0.0001 9,156/15,050 (60.8)
30.4 0.0001 32.5
11.4 0.0001 13.0lic Ftion
ystoli
)
0.8)
2.6)
1.4)
.6)F  left ventricular ejection fraction; MI  myocardial infarction.
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HF With Preserved Systolic Function in the ADHERE Database January 3, 2006:76–84ystolic dysfunction groups separately, elevated BUN and
ower systolic BP were confirmed as the most important
ortality predictors within each group. In addition,
ncreased heart rate was identified as a mortality predictor
n patient episodes of HF with PSF, but not in patient
pisodes of HF with systolic dysfunction. Multivariate
dds ratios (ORs) and corresponding 95% confidence
ntervals (CIs) for in-hospital death are reported for each
f the mortality risk factors previously identified by the
ART model (Table 7). The CART analysis in patients
ith new-onset HF identified the same mortality risk
actors (elevated BUN, low systolic BP, low serum
able 4. Use of Non-Intravenous and Intravenous Medications D
Medication
Preserved
(n  26,32
on-intravenous medications
Diuretic (%) 73.9
ACE inhibitor (%) 55.2
Patients without history of diabetes, n/total (%) 7,727/14,513
Patients with history of diabetes, n/total (%) 6,790/11,809
ARB (%) 15.1
ACE inhibitor or ARB (%) 67.0
Beta-blocker (%) 58.4
Patients without history of MI, n/total (%) 11,087/19,972
Patients with history of MI, n/total (%) 4,279/6,350 (
Digoxin (%) 25.7
Spironolactone (%) 12.5
ntravenous medications
Diuretic (%) 91
Diuretic, no. of vasoactive agents (%) 69
Vasoactive therapy (%) 23
Inotropes, any (%) 8
Dobutamine (%) 3
Dopamine (%) 5
Milrinone (%) 1
Vasodilator, any (%) 18
Nesiritide (%) 8
Nitroglycerin (%) 11
Nitroprusside (%) 1
Comparison between preserved and reduced systolic function groups.
Abbreviations as in Table 3.
able 5. Use of Non-Intravenous Medications at Discharge
Medication
S
Preserved
(n  26,322)
iuretic (%) 79.5
CE inhibitor (%) 47.1
Patients without history of diabetes, n/total (%) 6,606/14,508 (4
Patients with history of diabetes, n/total (%) 5,798/11,804 (4
RB (%) 13.2
CE inhibitor or ARB (%) 58.9
eta-blocker (%) 52.2
Patients without history of MI, n/total (%) 9,904/19,964 (4
Patients with history of MI, n/total (%) 3,841/6,348 (60
igoxin (%) 21.1
pironolactone (%) 10.6Comparison between preserved and reduced systolic function groups.
Abbreviations as in Table 3.odium concentration, and advanced age) as in all patient
pisodes with quantitative in-hospital LV ejection fraction
ssessment. Moreover, these findings were supported by mul-
iple logistic regression analyses (data not shown). Because
eart rate was selected as a mortality risk factor in several
ART and logistic regression models, it was added to the final
ist of adjustments, which included BUN, systolic BP, sodium,
ge, creatinine, heart rate, dyspnea at rest, and chronic beta-
locker use. Because adding second-order interaction terms
ncreased the predictive power of the model (as determined by
he area under the receiver-operator curve) by only 1%, these
erms were not included in the final model.
g Hospitalization
lic Function
p*
No LVEF Assessment
(n  45,607)
Reduced
(n  25,865)
79.5 0.0001 72.0
68.8 0.0001 51.5
10,765/15,393 (69.9) 0.0001 12,675/24,834 (51.0)
7,040/10,471 (67.2) 0.0001 10,820/20,770 (52.1)
12.9 0.0001 13.6
78.8 0.0001 63.0
68.6 0.0001 56.9
) 11,257/16,603 (67.8) 0.0001 16,324/30,543 (53.4)
6,492/9,261 (70.1) 0.0003 9,633/15,061 (64.0)
48.6 0.0001 36.5
27.4 0.0001 18.9
89 0.0001 85
56 0.0001 62
37 0.0001 26
19 0.0001 12
11 0.0001 6
10 0.0001 5
5 0.0001 3
24 0.0001 17
14 0.0001 10
12 0.0485 8
1 0.0227 1
c Function
p*
No LVEF Assessment
(n  45,607)
Reduced
(n  25,865)
83.7 0.0001 79.6
61.5 0.0001 46.2
9,683/15,387 (62.9) 0.0001 11,379/24,823 (45.8)
6,204/10,466 (59.3) 0.0001 9,689/20,763 (46.7)
11.0 0.0001 12.3
71.3 0.0001 57.4
62.6 0.0001 52.2
10,326/16,598 (62.2) 0.0001 14,918/30,531 (48.9)
5,866/9,255 (63.4) 0.0003 8,869/15,055 (58.9)
44.1 0.0001 33.1
24.7 0.0001 17.0urin
Systo
2)
(53.2)
(57.5)
(55.5
67.4)ystoli
5.5)
9.1)
9.6)
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January 3, 2006:76–84 HF With Preserved Systolic Function in the ADHERE DatabaseWhereas the adjustment for gender and race (percent
frican American) did not affect the mortality difference
etween the PSF and systolic dysfunction groups (unad-
usted OR: 0.70; 95% CI: 0.64 to 0.77; p 0.0001; and OR
fter adjustment for gender and race: 0.68; 95% CI: 0.61 to
.75; p  0.0001), the adjustment for gender, race, and
ight mortality risk factors reduced the magnitude of mor-
ality difference (adjusted OR: 0.86; 95% CI: 0.77 to 0.96;
 0.005). However, it remained statistically significant.
he Hosmer-Lemeshow test was not significant (p 0.16),
nd the area under the receiver-operator curve was 0.76,
ndicating that the final adjusted model provides an ade-
uate fit and a high degree of discrimination. Thus, the
ortality differences between the two systolic function
roups are real and are not accounted for by known risk
actors. Similar results were obtained in the subset of
atients with new-onset HF (9,758 patients with PSF vs.
,204 patients with systolic dysfunction): after adjustment
or gender, race, and eight risk factors, the mortality OR for
SF versus systolic dysfunction increased (unadjusted OR:
.68; 95% CI: 0.56 to 0.83; p  0.0001; and adjusted OR:
.79; 95% CI: 0.63 to 0.98; p  0.03), but remained
tatistically significant.
Patient episodes with renal insufficiency (serum creat-
nine 2 mg/dl) had significantly greater in-hospital
ortality regardless of LV function both before and after
djusting for gender, race, and mortality risk factors
Table 8).
able 6. Clinical Outcomes During Hospitalization
Outcome
P
(n 
ortality (%)
ength of hospitalization (days, median [interquartile range]) 4.9
dmitted to ICU (%)
ength of ICU/CCU stay (days, median [interquartile range]) 2.7
eight loss 10 lbs (%)
symptomatic at discharge (%)
Comparison between preserved and reduced systolic function groups.
CCU  coronary care unit; ICU  intensive care unit; LVEF  left ventricular
able 7. Multivariate* Odds Ratios and 95% Confidence Interval
Mortality Risk Factors
All Patient Episodes with
Quantitative LVEF
Assessment
ystolic BP 125 mm Hg 2.58 (2.33–2.86)
UN 37 mg/dl 2.53 (2.22–2.87)
odium 132 mmol/l 1.99 (1.76–2.26)
ge 73 yrs 1.76 (1.58–1.96)
yspnea at rest 1.55 (1.40–1.72)
r 1.5 mg/dl 1.39 (1.22–1.58)
o chronic beta-blocker 1.37 (1.23–1.51)
eart rate 78 beats/min 1.34 (1.20–1.49) 0.0001 unless noted otherwise. *Adjusted for all variables shown in the table. †p  0
BP  blood pressure; BUN  blood urea nitrogen; Cr  creatinine; LVEF  left venISCUSSION
his analysis of the ADHERE database, which involved
ore than 25,000 patient episodes of HF with PSF,
epresents the largest clinical evaluation of this population
o date. Data from the ADHERE database confirm find-
ngs of previous smaller studies and provide new insights
nto patient episodes of HF with PSF. The ADHERE
atabase clearly indicates that PSF is associated with one-
alf of all hospitalizations for HF. As noted before, patients
dmitted with HF and PSF are typically older and more
ikely to be women. Our data now provide additional
emographics and clinical characteristics and further de-
cribe the clinical presentation of this disorder. Observed
ifferences in treatment between the PSF and systolic
ysfunction groups reflect a lack of evidence-based strate-
ies for management of HF with PSF. However, even when
uch strategies exist, as in HF with systolic dysfunction, they
ay be infrequently followed; only 71% of patients with
ystolic dysfunction in this evaluation were prescribed an
CE inhibitor or ARB at hospital discharge. We have
emonstrated that the risk of in-hospital death is lower for
atient episodes of HF with PSF, but all other clinically
mportant outcomes are similar. Importantly, in-hospital
ortality risk factors are virtually identical for both
ystolic function groups with elevated BUN and lower
ystolic BP, the two most important predictors of in-
ospital mortality.
ystolic Function
p*
No LVEF Assessment
(n  45,607)
ed
322)
Reduced
(n  25,865)
3.9 0.0001 4.8
7.6] 5.0 [3.2–8.1] 0.0001 3.8 [2.3–6.1]
24.7 0.0001 15.3
4.9] 3.0 [1.6–5.1] 0.0001 2.0 [1.0–3.8]
80.7 0.0298 75.8
30.4 0.0001 23.2
55 0.21 51
n fraction.
Identified Mortality Risk Factors
Systolic Function
No LVEF
AssessmentPreserved Reduced
66 (2.28–3.11) 2.33 (2.03–2.68) 2.23 (2.03–2.44)
57 (2.11–3.14) 2.51 (2.12–2.97) 2.03 (1.81–2.28)
72 (1.40–2.12) 2.15 (1.83–2.52) 1.97 (1.76–2.21)
08 (1.74–2.48) 1.62 (1.41–1.85) 2.13 (1.92–2.36)
56 (1.34–1.82) 1.55 (1.35–1.77) 1.56 (1.42–1.71)
24 (1.02–1.52)† 1.50 (1.27–1.77) 1.37 (1.22–1.54)
51 (1.29–1.77) 1.28 (1.17–1.46) 1.60 (1.46–1.76)
55 (1.32–1.84) 1.14 (0.98–1.32)‡ 1.40 (1.27–1.54)S
reserv
26,
2.8
[3.1–
18.9
[1.4–
79.8
26.9
55s for
2.
2.
1.
2.
1.
1.
1.
1..03. ‡p  0.08.
tricular ejection fraction.
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ifferences between patient episodes of HF with PSF and
ith systolic dysfunction were the lower rate of prior
yocardial infarction and the higher rate of systolic hyper-
ension in the PSF group. Rales, peripheral edema, and a
istory of HF were common in both groups. It is quite
otable to observe the similarity of presentation character-
stics for patients with HF and either PSF or systolic
ysfunction. The use of bedside clinical assessment may not
e adequate to determine underlying ventricular function in
he setting of decompensated HF.
Consistent with the similarity in presentation and treat-
ent, the hospital course of patient episodes of HF with
ither PSF or systolic dysfunction is also quite similar. The
ength of stay is almost identical, and a similar proportion of
atient episodes are discharged with persistent symptoms.
pproximately 70% of the patients in both systolic function
roups were discharged with weight loss of 10 lbs, despite
vidence of congestion at presentation. This high rate of
eemingly ineffective therapy and persistent symptomatol-
gy is of concern and indicates an opportunity to improve
he quality of care. Given the presence of volume overload
e.g., rales and peripheral edema are found in nearly 70% of
atient episodes of HF with PSF), a reasonable target of
cute therapy might be more effective volume reduction.
Although the use of oral neurohormonal blocking agents
ncreased during hospitalization and at discharge, these
herapies were used significantly less often in patient epi-
odes of HF with PSF. Similar patterns of medication use
ere documented in previous studies of patients hospital-
zed for HF with PSF (2,3,6).
Among parenteral medications, diuretics were used in the
ast majority of admissions in both systolic function groups.
he use of intravenous vasoactive therapies was low, par-
icularly in patient episodes with PSF. The use of vasodi-
ators and nesiritide was significantly lower in the PSF
roup (vs. the systolic dysfunction group). The observed use
f inotropes is inexplicable given the known mortality risks
ssociated with these agents, the absence of a reasonable
ndication for use (i.e., cardiogenic shock or impending
ardiogenic shock), and the extremely low rate of frank
Table 8. Mortality According to Renal Functio
Category Pr
Mortality (Cr 2 mg/dl vs. Cr 2 mg/dl)
Unadjusted OR (95% CI) 2.12 (
Adjusted† OR (95% CI) 2.45 (
*Based on patients with available assessments of Cr at present
pulse, dyspnea at rest, and chronic beta-blocker use. No a
correlation of these variables and renal insufficiency status. ‡
with complete covariate information. The Hosmer-Lemesho
the curve was 0.73. §Based on the data for 24,396 patients wi
Hosmer-Lemeshow test was not statistically significant (p 
CI  confidence interval; Cr  creatinine; OR  oddsypotension in patient episodes of HF with PSF (14–16). HIt is apparent that evidence-based therapies for chronic
F with systolic dysfunction are frequently used in patients
ith PSF without data to substantiate the efficacy of this
pproach. In some cases, these medications may have been
sed to manage comorbidities such as hypertension, coro-
ary artery disease, and diabetes (which are present with
igh frequency in this patient population). Nevertheless,
linical trials evaluating the impact of these therapies in
atients with HF and PSF are clearly needed.
The data from the Candesartan in Heart Failure: Assess-
ent of Reduction in Mortality and Morbidity (CHARM)-
reserved trial would suggest at least a modest morbidity
enefit associated with chronic use of the ARB candesar-
an in patients with PSF (17). The ongoing Irbesartan in
eart Failure with Preserved Systolic Function trial is
valuating the ARB irbesartan in a similar patient popula-
ion. In the ADHERE database, fewer than 16% of patient
pisodes with documented HF and PSF were treated with
n ARB before, during, and after hospitalization, but this
ay change as the benefit of ARBs is more definitively
stablished.
There may be reasonable arguments to support the use of
eta-blockers in patients presenting with HF and PSF (e.g.,
linical benefits in hypertension and ischemic heart disease,
reduction in heart rate with a corresponding increase in
he diastolic filling period, the relief of ischemia with an
mprovement in compliance, the reduction in sympathetic
ctivation, and regression of ventricular hypertrophy), but
here have been no published clinical trials to date of
eta-blockers in this setting (18,19). Interestingly, our
ataset suggests an increased mortality risk associated with
n absence of chronic beta-blocker use in HF with PSF.
Aldosterone antagonists have a protean cardiovascular
rofile. Among the many described benefits of aldosterone
ntagonism is selective targeting of the extracellular matrix,
hich may improve ventricular compliance by retarding
ollagen deposition and reducing fibrosis (20,21). Available
ata indicate that aldosterone antagonists promote regres-
ion of ventricular hypertrophy and reduce the incidence of
udden cardiac death in patients with LV dysfunction, but
o data have yet been acquired specifically in the setting of
Systolic Function
d (n  26,002)* Reduced (n  25,447)*
% vs. 2.3% 8.4% vs. 2.9%
2.49); p  0.0001 3.11 (2.72–3.55); p  0.0001
2.92); p  0.0001‡ 2.72 (2.36–3.14); p  0.0001§
†Adjusted for gender, race, age, systolic blood pressure, sodium,
ent for blood urea nitrogen or Cr was made owing to high
on the data for 24,833 patients with preserved systolic function
was not statistically significant (p  0.59), and the area under
uced systolic function with complete covariate information. The
, and the area under the curve was 0.75.n
eserve
4.8
1.80–
2.07–
ation.
djustm
Based
w test
th redF with PSF (22–24).
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January 3, 2006:76–84 HF With Preserved Systolic Function in the ADHERE DatabaseWithin the Digitalis Investigation Group trial, the use of
igoxin was associated with an improvement in clinical
utcomes in the subset of patients with HF and PSF.
xplanations for this benefit are incompletely resolved (25).
Natriuretic peptides have been shown to exert positive
usitropic effects and are indicated in the management of
atients with acute decompensated HF (26,27). Within the
asodilatation in the Management of Acute CHF
VMAC) trial, nearly 15% of acutely symptomatic patients
ad HF with PSF (26). For each time point of data
ollection within the 3-h primary end point period, nesirit-
de led to a greater decrease in pulmonary capillary wedge
ressure than either nitrates or placebo (26).
Previous studies have established that patients with HF
nd PSF are at risk for adverse clinical outcomes. In a
opulation-based study, mortality risk of HF patients with
SF was four-fold greater than that of age- and gender-
atched controls without HF (28). Similar findings were
ecently reported for subjects with diastolic dysfunction but
ithout HF (29). In a recent study of 170 patients with HF,
igh rates of mortality and hospital readmission (during a
ean follow-up of 2.4 years) were evident both in patients
ith LV ejection fraction 40% and in those with LV
jection fraction 40%, without significant differences be-
ween the groups (6). Consistent with the results of these
arlier studies, the present analysis of the ADHERE data-
ase also demonstrates worrisome event rates for HF with
SF which, albeit lower than for HF with systolic dysfunc-
ion, do raise concerns and point out the lack of effective
anagement strategies for HF with PSF.
Renal insufficiency contributes to increased mortality in
atients with HF. The in-hospital mortality rates in the
SF and systolic dysfunction groups (2.8% and 3.9%,
espectively) are further increased in patients with baseline
erum creatinine 2.0 mg/dl (4.8% and 8.4%, respectively).
hus, renal insufficiency is a clear risk factor for in-hospital
ortality, regardless of LV function.
A unique contribution of this study is identification of
ortality predictors using the ADHERE database. Classi-
cation and regression tree analysis for all patients with a
uantitative in-hospital assessment of LV ejection fraction
dentified seven variables that were predictive of in-hospital
ortality. Among these variables, elevated BUN (37
g/dl) and lower systolic BP (125 mm Hg) were deter-
ined to be the strongest multivariate predictors of mor-
ality in the overall cohort of patient admissions for HF with
uantitative in-hospital assessment of LV ejection fraction
including both PSF and systolic dysfunction). These find-
ngs are consistent with our previously reported mortality
isk assessment for acute decompensated HF, but vary
lightly because the analysis was restricted to those with
uantitative in-hospital assessment of LV ejection fraction
30). Elevated BUN or reduced systolic BP were both
ssociated with a 2-fold increase in in-hospital mortality.
ther mortality predictors included elevated serum creati-ine, low serum sodium, increasing age, dyspnea at rest, and Un absence of chronic beta-blocker use in both systolic
unction groups. Increased heart rate, on the other hand,
as a risk factor for mortality in patient episodes of HF with
SF, but not in admissions for HF with systolic dysfunc-
ion. The prognostic value of mortality predictors in patient
pisodes with HF and quantitative in-hospital LV ejection
raction assessment also is evident for primary admissions
or HF, suggesting that the data are broadly applicable and
re not confounded by multiple readmissions in high-risk
atients.
tudy limitations. The ADHERE database is not a clin-
cal trial but a registry. As such, there are no treatment
equirements, randomization, or longitudinal follow-up.
ecause no patient identifiers are collected, patients may be
ntered in the registry more than once, and after-discharge
atient status cannot be assessed. The data are observa-
ional, and the analysis is retrospective. In addition, the
esults may be influenced by assessment and treatment
egimens that are not standardized and vary by institution.
he data presented apply to those patients with a recent
easurement of LV function, as the patient cohort without
n in-hospital assessment of LV ejection fraction differs
rom the primary cohort of patients with a measured LV
jection fraction. Therefore, these data should not be
xtrapolated to patients without a recent measurement of
V ejection fraction.
onclusions. This analysis from the ADHERE database
urther describes HF with PSF, especially in the context of
cute decompensation necessitating hospitalization. The
rofile of a patient presenting to the hospital with HF and
SF is now well characterized. Presentation and initial
anagement for HF with either PSF or systolic dysfunction
re quite similar. However, evidence-based treatment strat-
gies for HF with PSF are much less well established. The
DHERE database demonstrates significant in-hospital
ortality of patients with HF, regardless of LV function.
atient episodes of HF with PSF, however, are associated
ith lower in-hospital mortality than are episodes of HF
ith systolic dysfunction. Several variables appear to predict
n increased risk of death, most notably BUN 37 mg/dl
nd systolic BP 125 mm Hg. The mortality rates in both
he PSF and systolic dysfunction groups were increased in
he presence of impaired renal function (serum Cr 2
g/dl). It is apparent that the adverse outcomes are driven,
t least in part, by the lack of evidence-based treatment
lgorithms. The role of parenteral therapies in the manage-
ent of patients with HF and PSF clearly requires further
nvestigation. Newer therapies that alleviate symptoms and
mprove outcomes are needed for acute decompensated HF,
rrespective of LV function.
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